{
    "title": "First drug to slow Alzheimer\u2019s progression gets approved in the US and decision for the UK is \u2018on the horizon\u2019",
    "url": "https://www.dailymail.co.uk/health/article-12274633/First-drug-Alzheimers-progression-gets-approved-US.html",
    "date": "2023-07-07",
    "keywords": [
        "drug",
        "decision",
        "approval",
        "cent",
        "step",
        "disease",
        "dementia",
        "brain",
        "bleeding",
        "trial",
        "news",
        "progression",
        "leqembi",
        "move",
        "fight",
        "stock",
        "warning",
        "swelling",
        "risk",
        "process",
        "side",
        "uk",
        "review",
        "urgency",
        "treatment",
        "decline",
        "monthsthis",
        "equivalent",
        "slowdown",
        "company",
        "eisai",
        "tokyo",
        "biogen",
        "cambridge",
        "massachusetts",
        "week",
        "imageit",
        "earlystage",
        "impairment",
        "buildup",
        "amyloid",
        "protein",
        "brainsthe",
        "time",
        "meaning",
        "food",
        "administration",
        "fda",
        "evidence",
        "benefitthe",
        "portion",
        "drugaround",
        "placebothe",
        "boxed",
        "variant",
        "complicationstherefore",
        "testing",
        "patient",
        "readsthe",
        "read",
        "advertisement",
        "executive",
        "research",
        "world",
        "wakeup",
        "study",
        "healthcare",
        "agency",
        "mhra",
        "matter",
        "quality",
        "arent",
        "lecanemab",
        "reputation",
        "leader",
        "attract",
        "investment",
        "future",
        "care",
        "someone",
        "placebo",
        "imagewith",
        "horizon",
        "ready",
        "lecanemabprofessor",
        "david",
        "curtis",
        "university",
        "college",
        "london",
        "institute",
        "balance",
        "treatmentnevertheless",
        "illness",
        "aducanumab",
        "coverhowever",
        "benefit"
    ],
    "category": [
        "health"
    ]
}